848489-79-2

Upstream product

• 467-04-9 oripavine 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 

Downstream Products

• 1357076-49-3 3-O-benzyl-14-O-but-2-enyloxymorphinone 
• 26988-26-1 3-O-benzyl-14-hydroxymorphinone 
• 131575-15-0 3-(Benzyloxy)-7,8-didehydro-4,5α-epoxy-14β-methoxy-17-methylmorphinan-6-one 
• 16590-41-3 Naltrexone 
• 136232-95-6 buprenorphine hydrochloride 
• 52485-79-7 Buprenorphine 

Relevant academic research and scientific papers

PREPARATION OF BUPRENORPHINE

Disclosed are methods for preparing buprenorphine from, for example, compounds such as nororipavine and northebaine.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating chronic pain in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute pain (such as post-operative pain), palliative care to alleviate the severe, chronic, disabling pain of terminal conditions such as cancer, and degenerative conditions such as rheumatoid arthritis, non-malignant chronic pain, chemotherapy induced pain, musculoskeletal pain, sciatica, radiculopathy pain, migraine, neuropathic pain, post herpetic neuralgia, neuralgia pain, multiple sclerosis, multiple sclerosis, restless legs syndrome (RLS), cluster headache, depression, fibromyalgia and amyotrophic lateral sclerosis (ALS).

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN

The invention relates to the compounds of formula (I) and formula (II) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula 1 or formula II, and methods for treating chronic pain in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute pain (such as post-operative pain), palliative care to alleviate the severe., chronic, disabling pain of terminal conditions such as cancer, and degenerative conditions such as rheumatoid arthritis, non-malignant chronic pain, chemotherapy induced pain, musculoskeletal pain, sciatica, radiculopathy pain, migraine, neuropathic pain, post herpetic neuralgia, neuralgia pain, multiple sclerosis, multiple sclerosis, restless legs syndrome (R.l,S), cluster headache, depression, fibromyalgia and amyotrophic lateral sclerosis (A.LS).

PROCESSES FOR THE PRODUCTION OF 14 - OXYGENATED MORPHINAN - 6 - ONES

A process for the production of a 14-oxygenated morphinan-6-one of formula (I) wherein R1 is alkyl, alkenyl, alkynyl, cycloalkylalkyl, aralkyl, R3 is hydrogen, and R4 is hydrogen, wherein oripavine, 14-hydroxymorphinone or oxymorphone is used as starting material.

Process for the synthesis of 14-oxygenated morphinan-6-ones

A process for the production of 14-oxygenated morphinan-6-ones wherein a methylether group in position 3 of the phenyl ring which has to be cleaved to obtain the hydroxy group, and wherein the protection of the hydroxy group in position 3 of the phenyl ring in the presence of a ketal group is avoided.